Julia is a member of the firm's Healthcare, Life Sciences & Education team. While practicing in Missouri, she worked at Norton Rose Fulbright within its Healthcare Transactions group for nearly three years. Julia has had extensive experience handling various corporate, transactional, regulatory and antitrust matters, principally in the healthcare deal context.
Julia has helped to structure and support cutting-edge healthcare deals and to work through corresponding regulatory issues. She has worked with a variety of healthcare providers, including for-profit and nonprofit health systems, university hospitals, hospital districts and multispecialty physician groups, as well as pharmaceutical/medical device companies and private equity firms.
Julia's corporate experience includes drafting foundational agreements and corporate governance documents, due diligence coordination and review, and assessing entity debt in the bankruptcy and private equity context. She has also assisted clients to establish clinically integrated networks and Accountable Care Organizations (ACOs), including preparing the requisite corporate approvals for ACO creation, as well as ACO application documents.
Julia also has experience identifying and working through healthcare compliance issues, including arrangements that implicate healthcare fraud and abuse laws. She has supported the preparation of Anti-Kickback and Stark self-disclosures, and drafted client memoranda regarding the regulatory implications and permissibility of a proposed arrangement. In the deal context, Julia has performed extensive research and interfaced with state and federal regulatory bodies to address transfer, assignment and change of ownership/control issues implicated by a pending transaction, such as facility licensure, accreditation and certification (including Certificate of Need), Medicare/Medicaid approval and DEA licensing. Additionally, she has drafted HIPAA, physician contracting and other organizational policies, and helped to restructure provider arrangements to minimize compliance risk.